Crandell Keith's Form 4 filing
Seaport Therapeutics, Inc. (SPTX) · filed May 4, 2026
- Accession no.
- 0001193125-26-204458
- Filed
- May 4, 2026, 6:02 PM ET
- Trade date
- May 4, 2026
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market purchases total $19.8M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Crandell KeithCIK 0001219039 | 10% Owner |
| Nelsen RobertCIK 0001219042 | 10% Owner |
| Gillis StevenCIK 0001229592 | 10% Owner |
| Burow KristinaCIK 0001569248 | 10% Owner |
| ARCH Venture Fund XII, L.P.CIK 0001906837 | 10% Owner |
| ARCH Venture Partners XII, LLCCIK 0001979548 | 10% Owner |
| ARCH Venture Partners XII, L.P.CIK 0001979765 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 4, 2026 | Common Stock | CConversionAcquired | +2,513,686 | –F1 | – | 2,513,686 | Indirect | |
| May 4, 2026 | Common Stock | CConversionAcquired | +2,681,265 | –F1 | – | 5,194,951 | Indirect | |
| May 4, 2026 | Common Stock | PPurchaseAcquired | +1,100,000 | $18.00 | +$19,800,000 | 6,294,951 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 4, 2026 | Common Stock | CConversionDisposed | −2,513,686 | $0.00 | $0 | 0 | Indirect | |
| May 4, 2026 | Common Stock | CConversionDisposed | −2,681,265 | $0.00 | $0 | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each share of Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
Referenced by the price of 2 transactions in Table I.